Dubai: Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has appointed Ousama Al Haj as General Manager and Head of Human Pharma for Gulf area, effective June 1st, 2020. Drawing on more than 20 years’ experience in the multinational pharmaceutical industry and having proved himself as a transformational leader, Ousama joins Boehringer Ingelheim where he held various leadership positions in the Gulf and Levant countries, most recently as Country Director for UAE, Bahrain, Oman and Qatar.
“We warmly welcome Ousama to Boehringer Ingelheim and look forward to drawing on his wealth of experience to oversee operations across the UAE and wider Gulf area. This region plays a significant role in the global operations of our company, attributed to its growing population needs and investment in healthcare infrastructure. Our current focus places patients and innovation as the driving force behind all actions, thereby preparing us for the next wave of growth. We firmly believe Ousama will prove to be an invaluable asset to the team in this regard,” said Mohammed Al-Tawil, Country Managing Director and Head of Human Pharma META.
Ousama’s addition to the team comes at an opportune time for Boehringer Ingelheim Middle East, Turkey and Africa, as the division holds the recognition as being the third fastest growing pharmaceutical multinational in the Middle East, Turkey and Africa region. His efforts are expected to contribute to the continued strong performance and consistent growth of the firm within the market.
Since his onboarding, he has seamlessly and successfully managed cross-country teams through efficient utilization of digital capabilities. This has allowed for enhanced connection with stakeholders and further development of the team’s skillset through dedicated training courses. Ousama aims to carry on adapting operations to the ‘new normal’ and ensure continued commitment to patients and the healthcare industry during this time.
About Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com .
For more information, please contact:
Account Director | Healthcare
Head of External Communications – META
© Press Release 2020